Lantheus (LNTH)
(Delayed Data from NSDQ)
$112.50 USD
+0.54 (0.48%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.50 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$112.50 USD
+0.54 (0.48%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.50 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Here's Why You Should Add McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Bet on ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Zacks Industry Outlook Highlights QuidelOrtho, Lantheus and TG Therapeutics
by Zacks Equity Research
QuidelOrtho, Lantheus and TG Therapeutics are part of Zacks Industry Outlook article.
Centene (CNC) to Sell Magellan Arm, To Use Proceeds for Buybacks
by Zacks Equity Research
Centene (CNC) strikes a deal with Evolent to divest Magellan Specialty Health, a Magellan Health arm, to deepen focus on solidifying its core Managed Care business.
3 Medical Products Stocks Navigating Industry Challenges
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Lantheus Holdings (LNTH) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 19.28% and 4.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What Awaits Lantheus Holdings (LNTH) This Earnings Season?
by Zacks Equity Research
Lantheus Holdings' (LNTH) third-quarter results are likely to reflect solid top line results on the back of robust product adoption.
AMN Healthcare (AMN) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) third-quarter results are likely to reflect solid demand across all its segments.
How Investors Can Grab Better Returns for Medical Using the Zacks ESP Screener
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Lantheus Holdings (LNTH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Lantheus Holdings (LNTH) closed the most recent trading day at $75.45, moving +1.95% from the previous trading session.
Lantheus Holdings (LNTH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Lantheus Holdings (LNTH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why "Trend" Investors Would Love Betting on Lantheus Holdings (LNTH)
by Zacks Equity Research
Lantheus Holdings (LNTH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPSM
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Molina Healthcare (MOH) to Post Q3 Earnings: What to Expect
by Zacks Equity Research
Molina Healthcare's (MOH) Q3 results are expected to reflect better premiums and membership growth in its Medicaid and Medicare businesses, partly offset by steep general and administrative costs.
Lantheus Holdings (LNTH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Lantheus Holdings (LNTH) closed at $72.33, marking a +0.86% move from the previous day.
Lantheus Holdings (LNTH) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Lantheus Holdings (LNTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Lantheus (LNTH) This Year?
by Zacks Equity Research
Here is how Lantheus Holdings (LNTH) and Pharming Group N.V. Sponsored ADR (PHAR) have performed compared to their sector so far this year.
Why Lantheus Holdings (LNTH) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Lantheus Holdings (LNTH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Lantheus Holdings (LNTH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Lantheus Holdings (LNTH) closed the most recent trading day at $67.04, moving +1.22% from the previous trading session.
Lantheus Holdings (LNTH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Lantheus Holdings (LNTH) closed the most recent trading day at $77.67, moving +1.17% from the previous trading session.
Should SPDR S&P 600 Small Cap ETF (SLY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLY
Why Should You Retain Cigna (CI) in Your Portfolio Now?
by Zacks Equity Research
Cigna (CI) is aided by powerful segmental performances, solid demand for its Medicare plans, divestitures and solid cash-generating abilities.